10AA Human Clinical
Descapeptide-12
A ten-amino-acid tyrosinase inhibitor developed at Stanford — the first cosmeceutical peptide to match hydroquinone's potency at enzyme level without melanocyte cytotoxicity, effective at 0.01% concentration.
In Plain English:
Decapeptide-12, sold under the trade name Lumixyl (Envy Medical Inc.), is a synthetic ten-amino-acid peptide with the sequence Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr developed by dermatological researchers at Stanford University and first described by Basil M. Hantash MD PhD. The peptide acts as a direct, competitive inhibitor of tyrosinase — the copper-containing enzyme that catalyses the rate-limiting steps of melanogenesis (L-tyrosine → L-DOPA → dopaquinone). Unlike upstream-acting agents that target receptor signalling (e.g., Nonapeptide-1 at MC1R), Decapeptide-12 binds the C-terminal active site of the tyrosinase enzyme itself (Kd 61.1 μM), reversibly reducing its catalytic efficiency without destroying melanocytes or inducing post-inflammatory pigmentation. In vitro data shows 5.5-fold greater melanin reduction vs. hydroquinone at equivalent molar doses and 17-fold greater tyrosinase inhibitory potency. A 2013 open-label trial (n=33 Hispanic females, 16 weeks) using 0.01% decapeptide-12 combined with 20% buffered glycolic acid found mean MASI score reductions of 36% at week 4, 46% at week 8, 54% at week 12, and 60% at week 16, with zero adverse events (PMID 23839199). A 2012 open-label 24-week trial (n=13, Fitzpatrick I–IV) reported 38.5% of subjects achieving complete clearance of moderate photodamage (PMID 22401652). A 2014 clinical case report demonstrated 17-fold potency advantage over hydroquinone using SilkPeel dermalinfusion + twice-daily topical cream at Fitzpatrick IV (JDD 2014). A 2023 real-world multicenter retrospective study (n=65 vitiligo patients, Cureus PMID 37546028) using topical decapeptide lotion (Melgain) found 98% improvement and 71% achieving >75% repigmentation. Formulation challenge: the native peptide is hydrophilic (MW 1311–1395 g/mol) and has limited skin penetration; a 2021 pharmaceutical study (PMID 34242628) demonstrated that palmitate-conjugated 'palm-peptide' variants with oleic acid and menthol as permeation enhancers achieve therapeutic skin concentrations. Decapeptide-12 is INCI-registered, EU/US/UK cosmetic-compliant, does not photo-sensitise, and is well tolerated across all Fitzpatrick types I–VI including ethnic skin types where hydroquinone carries cytotoxicity risks. It is active at concentrations as low as 0.01% and is frequently combined with glycolic acid (AHA exfoliation) to synergistically accelerate clearance of hyperpigmented corneocytes.
Research Maturity
Human Clinical (~40 PubMed results; clinical evidence is open-label trials only, no large RCT+ Studies)
Focus
Pigmentation Modulation
Skin Health
Origin
Sequence H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH; one-letter code YRSRKYSSWY. Developed by Basil M. Hantash MD PhD and colleagues at Stanford University dermatology research program, circa early 2000s. Commercialised by Envy Medical Inc. as Lumixyl Topical Brightening System. INCI name: Decapeptide-12. CAS: 137665-91-9. Molecular formula: C65H90N18O17. Molecular weight: 1311.46 g/mol (free acid); 1395.52 g/mol (acetate salt form). InChI key: OYVFAMLECFSFEI-XJHNTGDTSA-N. PubChem CID: available under CAS 137665-91-9. EU CosIng functions: bleaching, skin conditioning. SpecChem commercial grade: SpecPed DE12P (Unifect UK distribution). Note: INCI spelling variant 'Decapaptide-12' appears in some older databases but Decapeptide-12 is the correct and primary registration.
Mechanism
Competitive inhibitor of tyrosinase (EC 1.14.18.1), a type-3 copper-containing enzyme housed in melanosomes. Tyrosinase catalyses two sequential reactions in melanogenesis: (1) hydroxylation of L-tyrosine to L-DOPA (monophenolase / cresolase activity); (2) oxidation of L-DOPA to dopaquinone (diphenolase / catecholase activity). Decapeptide-12 binds reversibly to the C-terminal domain of the tyrosinase enzyme (Kd = 61.1 μM against mushroom tyrosinase; IC50 = 40 μM against mushroom tyrosinase in competitive assay) — altering enzyme conformation and reducing turnover of phenolic substrates. The binding is reversible and non-cytotoxic: melanocytes remain viable and proliferating; only melanin output is reduced (27–43% melanin content reduction in cultured melanocytes, independent of cell proliferation). Secondary mechanism: Decapeptide-12 has also been reported to modulate transcription of the TYR gene on chromosome 11q21, increasing SIRT1 transcription (a melanogenesis suppressor). A 2024 oxidative stress study found enhanced HaCaT cell viability and reduced intracellular ROS levels, with antioxidative activity confirmed by FRAP and ABTS assays — suggesting anti-oxidant ancillary benefit. Synergistic mechanism: when co-applied with glycolic acid (20% buffered), AHA exfoliation accelerates removal of hyperpigmented corneocytes while Decapeptide-12 suppresses new melanin synthesis at the basal layer, producing faster clinical response than either agent alone.
Outcome
PMID 22401652 (Kassim, Hussain, Goldberg; J Cosmet Laser Ther 2012): Open-label, 24-week trial; n=13 females; Fitzpatrick I–IV; decapeptide-12 system (antioxidant cleanser + 0.01% decapeptide-12 cream + 20% glycolic acid moisturiser + SPF50 sunscreen); primary endpoint: photodamage grade. Results: 38.5% complete clearance (grade 3 → grade 1); 30.7% moderate → mild; 15.4% severe → moderate; 15.4% severe → mild. All treatments well tolerated; no cytotoxicity. // PMID 23839199 (Ramírez, Carvajal, Salazar et al.; J Drugs Dermatol 2013): Open-label, prospective, multicenter; n=33 Hispanic females; 0.01% decapeptide-12 + 20% buffered glycolic acid; 16 weeks. MASI score reductions: 36% at week 4, 46% at week 8, 54% at week 12, 60% at week 16 (p<0.001). Zero adverse events. Conclusion: safe and efficacious for mild-to-moderate melasma in Hispanic females. // Bhatia, Hsu, Hantash (J Drugs Dermatol Jan 2014): Case report, Fitzpatrick IV, recalcitrant PIH; 4× SilkPeel dermalinfusion (0.01%, 80–100 grit, 4.5 psi vacuum) + twice-daily topical decapeptide-12 cream. Result: accelerated resolution of PIH; Decapeptide-12 found to be 17-fold more potent tyrosinase inhibitor than hydroquinone in this clinical context. // PMID 34242628 (Chen, Bian, Hantash et al.; Int J Pharmaceutics 2021): Delivery study — palmitoyl-decapeptide-12 ('palm-peptide') with oleic acid + menthol achieves best skin retention; microneedles enhance native peptide penetration; palm-peptide reaches therapeutic concentrations in skin tissue. // PMID 37546028 / PMC10403243 (Sharma, Majid, Kumar et al.; Cureus 2023): Retrospective multicenter real-world study; n=65 vitiligo patients; topical decapeptide lotion (Melgain); 98% of patients showed improvement; 71% (n=46) achieved marked response (>75% repigmentation); 96.92% excellent tolerability; one patient minor local reaction (erythema/burning, self-resolving). // Pilot study (internal Envy Medical data, cited in multiple JDD papers): split-face, double-blind, randomised, placebo-controlled; n=5; Fitzpatrick IV; recalcitrant melasma; 0.01% decapeptide-12 emulsion twice daily; 40% melasma improvement at 12 weeks, 50% at 16 weeks. In vitro benchmark: 27–43% melanin content reduction in cultured melanocytes; 5.5× more effective than hydroquinone at equivalent molar dose in moderating melanin.
